Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732654 · ClinicalTrials.gov registry record · Phase 1
The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
A Phase 1 study of Milk Allergy, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00732654 is a Phase 1 study of Milk Allergy that has completed, run by Johns Hopkins University. The registered enrollment target is 30 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00732654, a Phase 1 study of Milk Allergy, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if small oral and sublingual doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.
Conditions Studied
Interventions
- DRUG Milk Protein Extract Immunotherapy goal of 4mg/day
- DRUG Milk Protein Extract Immunotherapy goal of 7mg/day
- DRUG Milk Powder Immunotherapy goal dose 2000 mg/day
- DRUG Milk Powder Immunotherapy goal dose 1000mg/day
Study Locations (2)
Maryland
- Johns Hopkins Hospital - Baltimore
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732654
The ClinicalTrials.gov registry entry for NCT00732654 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Milk Allergy appearing as the primary indexed condition, and to 4 interventions - of which Milk Protein Extract Immunotherapy goal of 4mg/day is the first listed.
NCT00732654 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00732654 about?
NCT00732654 is a clinical study titled "The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy". The purpose of this study is to determine if small oral and sublingual doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.
What is the current status of trial NCT00732654?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-08. Estimated completion is 2012-06.
What conditions does trial NCT00732654 study?
This clinical trial studies the following conditions: Milk Allergy.
What interventions are being tested in trial NCT00732654?
The interventions under investigation include: Milk Protein Extract Immunotherapy goal of 4mg/day (DRUG), Milk Protein Extract Immunotherapy goal of 7mg/day (DRUG), Milk Powder Immunotherapy goal dose 2000 mg/day (DRUG), Milk Powder Immunotherapy goal dose 1000mg/day (DRUG).
Who is sponsoring clinical trial NCT00732654?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00732654 being conducted?
This trial has 2 study locations across Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.